Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature

Table 1

Case number	Age	Gender	Diagnosis	Dasatinib dose	Time to hypopigmentation (Months)	References
Current case	12	Male	chronic myeloid leukemia	70 mg once daily	18	Current case
1	72	Male	chronic myeloid leukemia	100 mg once daily	37	[8]
2	52	Female	Hemangiopericytoma	70 mg twice daily	2	[9]
3	27	Female	chronic myeloid leukemia	100 mg once daily	6	[10]
4	16	Male	Acute lymphoblastic leukemia	100 mg twice daily	1	[11]
5	56	Female	chronic myeloid leukemia	70 once daily	2	[12]
6	29	Female	chronic myeloid leukemia	70 once daily	2	[13]